SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories submits press release

03 Jul 2019 Evaluate

Dr. Reddy’s Laboratories has informed about submission of a press release on ‘Dr. Reddy's Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (lmL) Single-dose Vial in the US Market’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Labs. Share Price

1369.55 23.30 (1.73%)
03-Jul-2026 11:09 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1920.35
Dr. Reddys Labs. 1369.55
Cipla 1459.60
Zydus Lifesciences 1118.00
Lupin 2465.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: